Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose?

Drugs

Volumn 72, Issue 13, 2012, Pages 1713-1723

  Bannwarth, Bernard ^a  

^a HÔPITAL PELLEGRIN   (France)

Author keywords

Buprenorphinenaloxone; Morphine; Morphinenaltrexone; Naltrexone; Niacin; Opioid abuse; Opioid analgesics; Oxycodone; Oxycodoneniacin; Pain; Pentazocinenaloxone; Substance related disorders

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; MORPHINE; MORPHINE SULFATE PLUS NALTREXONE; NALOXONE PLUS PENTAZOCINE; NARCOTIC ANALGESIC AGENT; NICOTINIC ACID; NICOTINIC ACID PLUS OXYCODONE; OPIATE; OXYCODONE;

BURNING SENSATION; CHILL; CONSTIPATION; CONTROLLED DRUG RELEASE; DIZZINESS; DRUG ABUSE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG FORMULATION; DRUG MISUSE; DRUG OVERDOSE; DRUG SAFETY; EUPHORIA; FLUSHING; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERHIDROSIS; MAXIMUM PLASMA CONCENTRATION; MORBIDITY; MORTALITY; NASAL PRURITUS; NAUSEA; NOSE CONGESTION; NOSE IRRITATION; PHARMACODYNAMICS; POSTOPERATIVE PAIN; PRESCRIPTION; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; SOMNOLENCE; TABLET; VOMITING;

ANALGESICS, OPIOID; CHEMISTRY, PHARMACEUTICAL; DRUG COMBINATIONS; DRUG DISCOVERY; DRUG OVERDOSE; DRUG PRESCRIPTIONS; HUMANS; MORPHINE; NALTREXONE; OPIOID-RELATED DISORDERS; PAIN;

EID: 84865632957     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11635860-000000000-00000     Document Type: Review

References (35)

1. Dhalla IA, Persaud N, Juurlink DN. Facing up to the prescription opioid crisis [published erratum appears in BMJ 2011;343:d5729]. BMJ 2011;343:d5142
2. Grady D, Berkowitz SA, Katz MH. Opioids for chronic pain. Arch Intern Med 2011;171(16):1426-7
3. Manchikanti L, Fellows B, Ailinani H, et al. Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. Pain Physician 2010;13:401-35
4. Nicholson B. Responsible prescribing of opioids for the management of chronic pain. Drugs 2003;63(1):17-32 (Pubitemid 36132511)
5. Woodcock J. A difficult balance: pain management, drug safety, and the FDA. N Engl J Med 2009;361(22):2105-7
6. Bannwarth B. Irrelevance of the WHO analgesic ladder for managing rheumatic pain. Joint Bone Spine 2010;77(1):1-3
7. United Nations Office on Drugs and Crime. World drug report 2011 [online]. Available from URL: http://unodc.org/unodc/en/data-and-analysis/WDR- 2011.html [Accessed 2012Mar. 30]
8. Okie S. A flood of opioids, a rising tide of deaths [published erratum appears in N Engl J Med 2011;364:290]. N Engl J Med 2010;363(21):1981-5
9. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescription for chronic pain and overdose: a cohort study. Ann Intern Med 2010;152(2):85-92
10. Bohnert A S B, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdoserelated deaths. JAMA 2011;305(13):1315-21
11. Hall AJ, Logan JE, Toblin RL, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA 2008;300(22):2613-20
12. Dhalla IA, Mamdani MM, Sivilotti M L A, et al. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. CMAJ 2009;181(12):891-6
13. Katz NP, Adams EH, Chilcoat H, et al. Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain 2007;23(8):648-60 (Pubitemid 47462170)
14. Holmes D. Prescription drug addiction: the treatment challenge. Lancet 2012;379:17-8
15. Centers for Disease Control and Prevention (CDC). Vital signs: overdoses of prescription opioid pain relievers - United States, 1999-2008. MMWR Morb Mortal Wkly Rep 2011;60(43):1487-92
16. Fishbain DA, Cole B, Lewis J, et al. What percentage of chronic non-malignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidencebased review. Pain Med 2008;9(4):444-59 (Pubitemid 351722518)
17. Fields HL. Should we be reluctant to prescribe opioids for chronic non-malignant pain. Pain 2007;129:233-4 (Pubitemid 46754579)
18. Passik SD. Issues in long-term opioid therapy: unmet needs, risks, and solutions. Mayo Clin Proc 2009;84(7):593-601
19. Webster LR, Cochella S, Dasgupta N, et al. An analysis of the root causes for opioid-related overdose deaths in the United States. Pain Med 2011;12 Suppl. 2:26-35S
20. Centers for Disease Control and Prevention (CDC). Emergency department visits involving nonmedical use of selected prescription drugs - United States, 2004-2008. MMWR Morb Mortal Wkly Rep 2010;59(23):705-9
21. Kuehn BM. Scientists probe ways to curb opioid abuse without hindering pain treatment. JAMA 2007;297(18):1965-7 (Pubitemid 46740365)
22. Centers for Disease Control and Prevention (CDC). Communitybased opioid overdose prevention programs providing naloxone - United States, 2010. MMWR Morb Mortal Wkly Rep 2012;61(6):101-5
23. Gugelmann HM, Perrone J. Can prescription drug monitoring programs help limit opioid abuse? JAMA 2011;306(20):2258-9
24. Raffa RB, Pergolizzi Jr JV. Opioid formulations designed to resist/deter abuse. Drugs 2010;70(13):1657-75
25. Webster LR, Bath B, Medve RA. Opioid formulations in development designed to curtail abuse: who is the target? Expert Opin Invest Drugs 2009;18(3):255-63
26. Webster L, St Marie B, McCarberg B, et al. Current status and evolving role of abuse-deterrent opioids inmanaging patients with chronic pain. J Opioid Manag 2011;7(3):235-45
27. Schneider JP, Matthews M, Jamison RN. Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse? CNS Drugs 2010;24(10):805-10
28. US Department of Health and Human Services. US Food and Drug Administration. Oxy Contin: questions and answers [online]. Available from URL: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm207196.htm#4 [Accessed 2012 Aug. 1]
29. Mastropietro DJ, Omidian H. Current approaches in tamperresistant and abuse-deterrent formulations. Drug Dev Ind Pharm. Epub 2012 Apr. 26
30. Smith HS. Morphine sulfate and naltrexone hydrochloride extended release capsules for the management of chronic, moderate-to-severe pain, while reducing morphine-induced subjective effects upon tampering by crushing. Expert Opin Pharmacother 2011;12(7):1111-25
31. Ruan X. Sustained-release morphine sulfate with sequestered naltrexone for moderate to severe pain: a new opioid analgesic formulation and beyond. Expert Opin Pharmacother 2011;12(7):999-1001
32. US Department of Health and Human Services. US Food and Drug Administration. Label approved on 07/09/2012 for EMBEDA. FDA Application No (NDA) 022321 [online]. Available from URL: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2012/022321s007lbl.pdf [Accessed 2012 Aug. 2]
33. Daniels SE, Spivey RJ, Singla S, et al. Efficacy and safety of oxycodone HCl/niacin tablets for the treatment of moderateto-severe postoperative pain following bunionectomy surgery. Curr Med Res Opin 2011;27(3):593-603
34. US Department of Health and Human Services. US Food and Drug Administration. Label approved on 06/17/2011 for OXECTA. FDA Application No (NDA) 202080 [online]. Available from URL: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2011/202080s000lbl.pdf [Accessed 2012 Aug. 1]
35. Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med 2012;367(2):187-9